Replies to post #109217 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

If LPC can buy at 4 then I think it will probably go to 4 cents, more or less. It was three cents just a year ago. I am picking three to four cents.

The differences between now and then. The numbers were going to come in, in the 90s for Lympro, looking at Lympro as a differentiator between dementias when they only tested Pd dementia v AD dementia. Those numbers came in, in the 70s and 80s and were not tested as dementia differentiators, but ad v healthy patients

Eltoprazine cannot get started for lack of performance of the checklist recently issued by AMBS.

MANF is closer to something, more than likely a sale of the company. The company has absolutely no leverage in that situation, EXCEPT for the fact that they have LPC's funding, so they will be able to hang in there until 2016.

Given the extreme dilution, a valuation of three cents is in line with the assets of AMBS. Of course these things range, based on PRs, but the notion that things are progressing at AMBS is very funny.

[Solantey]

Wait until L.P.C. buys before placing a bet.